Articles Published in 2012

Almac expands U.K. capacity with the acquisition of blistering tech

Wednesday, October 3, 2012 03:24 PM

Almac, a global service provider, has expanded its MHRA/FDA approved U.K. commercial packaging facility with the acquisition of a state-of-the-art Noack N 623 blister packaging line from Romaco.

More... »

Innova, Goodmark Medical to set up international operations in Scotland

Wednesday, October 3, 2012 02:58 PM

Innova Partnerships, a life science investment and partnering company based in Boston and Scotland, is working Goodmark Medical of Longwood, Fla., to help them expand into international markets.

More... »

LabRoots launches new social networking site for scientists

Wednesday, October 3, 2012 11:34 AM

LabRoots, a social networking site designed to connect all science verticals, has launched a new website.

More... »

LEO Pharma unveils new scientific collaboration strategy

Wednesday, October 3, 2012 11:08 AM

LEO Pharma, a global pharmaceutical company specializing in dermatology and critical care, plans to establish five long-term, strategic research collaborations in Australia, France, Germany and the U.S. by the end of next year.

More... »

Icon partners with KoNECT to advance S. Korean clinical trials industry

Wednesday, October 3, 2012 10:43 AM

Icon,a global provider of outsourced development services, and Korea National Enterprise for Clinical Trials (KoNECT) have signed a partnership agreement that aims to advance the clinical trials industry in South Korea.

More... »

Oramed Pharma, Medpace collaborate on phase II FDA trial of oral insulin

Wednesday, October 3, 2012 10:19 AM

Oramed Ltd., a subsidiary of Oramed Pharmaceuticals, a developer of oral drug delivery systems, has signed an agreement to retain Medpace as a full-service CRO for Oramed's upcoming phase II clinical trial on its oral insulin capsule, ORMD-0801.

More... »

Janssen to develop, commercialize Astellas’ ASP015K for immunologic diseases

Wednesday, October 3, 2012 09:52 AM

Janssen Biotech and Astellas Pharma have formed a license agreement whereby Janssen gains the exclusive right to develop and commercialize ASP015K, an Astellas compound, worldwide except for Japan.

More... »

Hagop Kantarjian joins Actinium Pharmaceuticals’ clinical advisory board

Wednesday, October 3, 2012 09:39 AM

Actinium Pharmaceuticals (API), a New York-based biopharmaceutical company focused on immunotherapeutics, has appointed Hagop Kantarjian, MD, to the company's clinical advisory board. 

More... »

Third Rock Ventures names entrepreneur-in-residence

Tuesday, October 2, 2012 01:57 PM

Boston-based Third Rock Ventures, a venture capital firm focused on building life sciences companies, has named Felix W. Frueh, Ph.D., an entrepreneur-in-residence (EIR). As an EIR, Dr. Frueh will provide strategic input on new and existing portfolio companies with a particular focus on personalized medicine.

More... »

BioInvent focuses its business, reduces staff

Tuesday, October 2, 2012 01:54 PM

Sweden-based BioInvent International has decided to focus its operations with the aim of achieving self-financing of the business before external costs for future new clinical studies. Its development of proprietary antibody drugs will concentrate primarily on developing new cancer drugs, resulting in a clear indication focus. The company currently has five agreements with major companies based on products from the antibody library, n-CoDeR. It will increase the efforts to create new n‑CoDeR agreements for clinical programs and continue to develop existing partnerships.

More... »